RSV lower respiratory tract disease
Vaccines · 2024–2026
5decisions
4medicines
3carried consumer input
39individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| respiratory syncytial virus vaccine, recombinant, pre-fusion F protein 3, older adult Prevention of RSV-confirmed lower respiratory tract disease (LRTD) in adults aged ≥75 years, First Nations adults aged 60-74 years, and adults aged 60-74 years… | Mar 2026 | Recommended | unclear |
| nirsevimab Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in… | May 2025 | Deferred | 15 individuals |
| mRNA-1345 Prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged ≥75 years and Aboriginal and Torres Strait… | Nov 2025 | Deferred | no section in document |
| nirsevimab Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and… | Jul 2024 | Not recommended | 15 individuals Lung Foundation Australia · Asthma Australia · Immunisation Foundation · Other Respiratory Illnesses Community Reference Group · Pediatric Infectious Diseases Society |
| respiratory syncytial virus vaccine, recombinant pre-fusion F protein 3 older adult (RSVPreF3 OA) Prevention of RSV-confirmed lower respiratory tract disease (LRTD) in older adults. The submission requested NIP listing for adults aged ≥60 years (TGA… | Jul 2024 | Not recommended | 9 individuals Immunisation Foundation · Lung Foundation Australia · Asthma Australia · National Asthma Council Australia |
Who spoke
Lung Foundation Australia · Asthma Australia · Immunisation Foundation · Other Respiratory Illnesses Community Reference Group · Pediatric Infectious Diseases Society · National Asthma Council Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.